Takeda Pharmaceutical Company Limited shared positive interim findings from its Phase 1b trial of mezagitamab for IgA nephropathy. Kidney function remained stable through Week 96, 18 months after the final dose. IgA nephropathy is a progressive autoimmune disease affecting young people, with no cure and a high risk of renal failure. These results were presented at ASN Kidney Week 2025. For more health news, visit rttnews.com. (RTTNews)

IgA nephropathy is a lifelong autoimmune disease that damages kidney function, often affecting young individuals. Despite available treatments, about one in five patients may experience renal failure within a decade of diagnosis. Mezagitamab, an anti-CD38 monoclonal antibody, showed promising results in stabilizing kidney function in patients with IgA nephropathy. These findings were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston. (RTTNews)

Read more at Nasdaq: Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy